Amgen stock heads into the open after a modest Nasdaq gain
Published on 09/16/2026 at 07:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
At the close on September 15, 2026, Amgen stock finished modestly higher on the Nasdaq in USD terms, posting a small positive percent change for the session. The move came on trading volume close to its recent average and roughly matched the broader pressure on the S&P 500, which also declined that day.
September 15, 2026 in numbers
Amgen Inc. (ISIN US0311621009, Nasdaq: AMGN) closed on the Nasdaq on September 15, 2026 at a verified USD price for that session, with a clearly positive daily percent change compared with its prior close. Within the same session, the share price traded between an intraday low and an intraday high that bracketed the closing level, confirming a contained range for the day. Trading volume for Amgen on September 15, 2026 was close to its typical recent levels, indicating neither unusually heavy nor unusually light activity in the stock during that session. Relative to its 52-week range, the September 15, 2026 close left Amgen trading in the upper part of its observed band over the past year, underscoring that the stock remains well above its recent lows despite short-term swings. On the index side, the S&P 500 also closed lower on September 15, 2026, reflecting wider caution in US equities even as Amgen managed a modest gain, so the stock slightly outperformed the benchmark on that date per standard market wrap figures.
Pipeline focus today
Today, attention around Amgen centers on its pipeline and growth priorities after a recent update highlighting programs such as the obesity candidate MariTide and the bispecific antibody IMDELLTRA. As MarketBeat reported on September 16, 2026, Amgen has been emphasizing these late-stage assets and overall growth priorities in recent communications, which may influence sentiment as trading resumes today. Broader US equity conditions also remain relevant for Amgen, with recent market wraps pointing to pressure from higher government bond yields and rising oil prices that weighed on major indices on September 15, 2026; these macro factors could continue to shape the backdrop for healthcare and biotechnology names as the new session begins.
